Sanofi funds stalled Genzyme programs; Amgen broadens Brazilian reach;

 @FierceBiotech: AstraZeneca wins tightly-limited FDA OK for new thyroid cancer drug. Report | Follow @FierceBiotech  

 @JohnCFierce: The FDA says that it has taken steps to safeguard data after a chemist was accused of using insider information. Story | Follow @JohnCFierce

> Sanofi-Aventis has bankrolled three stalled Genzyme programs and will support up to three more as the Paris-based developer begins the process of integrating its recent acquisition. "I had not appreciated the degree to which Genzyme had been financially constrained over the last couple of years,'' explained CEO Chris Viehbacher in a Boston Globe article. Much of Genzyme's time and money has been spent fixing a string manufacturing issues. Article

> Amgen has purchased Brazilian pharma company Bergamo for $215 million in an effort to grow its reach in the country. In addition, the company agreed to transfer the Brazilian rights to three of its drugs--Vectibix, Mimpara and romiplostim--from Hypermarcas. Amgen release

> Indian biotech Cadila Healthcare received FDA approval to start Phase I trials for ZYGK1, a type 2 diabetes treatment. The drug is a glucokinase activator that regulates the metabolism of insulin in the liver. Story

> Regeneron and Bayer have announced the start of two Phase III trials for the eye solution VEGF Trap-Eye for macular edema. One trial will be conducted by Regeneron and is based in North America, while Bayer commands a study in Australia, Europe and Japan. Release

Pharma News

@FiercePharma: Analyst: J&J may need a $10 billion-plus deal. News | Follow @FiercePharma 

> J&J picks Torres to deal with McNeil nitty-gritty. News

> Government shutdown threatens FDA work. Report

> Amgen CEO Sharer gets 38% pay increase to $21M. Story

> GSK readies 500 reps for Horizant launch. Article

> Labor agency jumps into another sales-rep overtime case. Item

And Finally... Researchers have found omega-3 fatty acids can combat the effects of extended exposure of estrogen, which can include a heightened risk of breast cancer. Fish oil acts in the same manner as the breast cancer drug tamoxifen, and a high fish oil diet with tamoxifen treatment provided the best results in the study. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.